List of Receptors
Receptor | Organism | Cell type | Mechanism of raft association | Methods used to detect raft association | Functional implication |
---|---|---|---|---|---|
α1-adrenoreceptor |
Rat 1 |
Bound caveolin-3 1 |
Detergent-free 1 |
n.a |
|
β1-adrenoreceptor |
Rat 2 |
COS-7 cells 3, Cardiomyocytes 2, Cardiac fibroblastas 4; Neonatal myocytes 5 |
Bound caveolin-1 3 |
No functional implication observed upon agonist treatment or raft disruption 4, 5 |
|
β2-adrenoreceptor |
COS-7 cells 3, Cardiomyocytes 4; Cardiac fibroblastas 4; Neonatal myocytes 5; bronchial smooth muscle cells 6; HEK-293 6 |
Bound caveolin-13 |
Agonist treatment leads to movement out of caveolae 4; Caveolae disruption by filipin or cyclodextrin increased cAMP accumulation and contraction rate 5' 4; The receptor colocalized with Adenylyl scyclase 6 (AC6) in lipid raft fractions 6. |
||
β3a-adrenoreceptor |
Putative caveolin binding domain 7 |
Filipin treatment alters accumulation of c-AMP 7; Filipin III treatment, caveolin-1 knockdown and caveolin-binding motif mutation of receptor promote pertussis toxin (PTX) sensivity of the receptor which indicating Gαi/0 coupling. It is suggested that receptor interaction with caveolin inhibits coupling to Gαi/0 proteins 8. . |
|||
δ-opioid receptor |
Ventricular myocytes 9; Neuroblastoma ×glioma NG108-15 hybrid cell 11, 10; CHO cells 10 |
Associates with caveolin-3 9 |
Detergent-free 9, 10; Immunprecipitation 9; Detergent-dependent fractionation 11 |
MβcCD treatment attenuates cardiac protection from ischemic damage 9; Cav1 and cav3 expression attenuates N-type Ca2+ channels inhibition induced by receptor agonist 11; Agonist induced receptor movement out of lipid raft 10; MβCD treatment attenuates receptor-mediatied signaling in neuronal cells but increased it non-neuronal cells 10 |
|
κ-opioid receptor |
Human 12 |
n.a |
Detergent-free 12 |
MβCD treatment increased p42/44 MAPK phosphorylation 12 |
|
μ-opioid receptor |
n.a |
Detergent-free 13, 14; Confocal microscopy 14; Detergent-dependent 15 |
MβCD treatment inhibited receptor internalization and adenylyl cyclase superactivation 13; Agonist etrophine induced receptor movement out of raft 14; MβCD treatment attenuated etrophine- and morphine-meidated adenyly cyclase inhibition and morphine-induced but not etrophine-induced ERK phosphorylation 14 |